Overview

A Phase II Trial to Evaluate the Effect of Itraconazole on Pathologic Complete Response Rates in Resectable Esophageal Cancer

Status:
Not yet recruiting

Trial end date:
2028-12-15

Target enrollment:

Participant gender:

Summary

Esophageal cancer, which has a low 5-year overall survival rate (<20%) is increasing in incidence. Previous studies have shown that Hedgehog, AKT, and angiogenic signaling pathways are activated in a significant number of esophageal cancers. Itraconazole, a widely used anti-fungal medication, effectively inhibits these pathways. In this multi-site phase II trial, the investigators will evaluate the effect of itraconazole as a neoadjuvant therapy added to standard of care chemoradiation and surgery in the the treatment of locoregional esophageal and gastroesophageal junction cancers.

Phase:

Phase 2

Details

Lead Sponsor:

VA Office of Research and Development

Collaborators:

Durham VA Health Care System
Michael E. DeBakey VA Medical Center
Portland VA Medical Center
VA Boston Healthcare System
VA Palo Alto Health Care System
VA Puget Sound Health Care System

Treatments:

Itraconazole